Trilaciclib protects bone marrow before SCLC chemotherapy, sharply reducing neutropenia, anemia, and thrombocytopenia, improving fatigue and keeping treatment on schedule without weakening tumor kill.

The University of Iowa Health Care Holden Comprehensive Cancer Center has started treating its second patient — the second in the state — with a cellular therapy to fight synovial sarcoma, a rare and ...

Newsnight presenter Victoria Derbyshire opened up about the importance of strength and exercise training following her 10-month battle with breast cancer in 2015. Over a decade later, HELLO! asked a p ...

A Virginia high school junior is facing months of chemotherapy and surgery after a sudden diagnosis of rare bone cancer. Colton Marquise, a 17-year-old junior at Fauquier High School, was diagnosed ...

Indian hospitals are witnessing early signs of a slowdown in high-value medical tourism as escalating tensions in the Middle East create uncertainty around travel and patient mobility. The region is a ...

Ongoing activities, including new engagement to relist on Nasdaq, new board member, continued advancement of Phase 1 trial into MDS patients, strategic engagement, and continued support from lead inve ...

Reported interim data from ADVANCED-2 trial in non-muscle invasive bladder cancer (NMIBC); TARA-002 demonstrated 68% complete response rate at six months in BCG-Unresponsive patients Company expects ...

Learn how Huntsman Cancer Institute uses cutting‑edge diagnostics and personalized care to treat early‑stage prostate cancer. Discover why early detection makes treatment more effective and far less ...

A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...

A recent study published in Engineering has shed light on a novel therapeutic target for improving anti-angiogenic treatment in colorectal cancer (CRC). The research, conducted by an international ...